DOCS Boosts Client Retention via Workflow Integration and AI Tools

Doximity (DOCS) is focused on client engagement and retention through deeply integrated, physician-first tools, with over 620,000 providers using its clinical tools in Q4 2025; the company leverages AI and machine learning to deliver personalized marketing campaigns and has embedded workflow solutions like Dialer Enterprise into hospital operations, reducing churn. GoodRx (GDRX) is enhancing pharmacy engagement via Community Link and an Integrated Savings Program, while Veeva Systems (VEEV) is strengthening client engagement through its Vault CRM Suite. Doximity shares have gained 9.6% year-to-date, outperforming the industry, and fiscal 2026 EPS is projected to improve 3.5% from fiscal 2025.

Analysis

Doximity, Inc. (DOCS) demonstrates a robust client engagement and retention model centered on deeply integrated, physician-first tools, evidenced by over 620,000 unique providers utilizing its clinical offerings in Q4 fiscal 2025. The company effectively leverages AI and machine learning within its Marketing Solutions to deliver personalized campaigns, fostering measurable engagement and encouraging expanded client usage. Furthermore, its Workflow Solutions, including Dialer Enterprise and AMiON, are deeply embedded into hospital operations, significantly reducing churn potential, with recent additions like the AI-powered Doximity GPT aimed at further enhancing value by reducing administrative burdens. This strategic focus on high clinical utility and workflow integration creates substantial platform stickiness. While Doximity's shares have gained 9.6% year-to-date, outperforming the industry's 0.9% loss, its forward 12-month P/E ratio of 39.4X is considerably higher than the industry average of 14.6X, though it is below its own three-year median of 48.9X. The Zacks Consensus Estimate for fiscal 2026 earnings per share indicates a modest 3.5% improvement from fiscal 2025, and the stock currently holds a Zacks Rank #3 (Hold) and a Value Score of D, suggesting a mixed valuation picture despite strong operational execution and market outperformance. Competitors like GoodRx (GDRX) and Veeva Systems (VEEV) are also pursuing similar client engagement strategies, underscoring the importance of continuous innovation in this space.

Key Decisions for Investors

• Investors should weigh Doximity's strong platform stickiness, driven by its integrated workflow solutions and AI adoption, against its premium valuation reflected in a forward P/E of 39.4X and a projected fiscal 2026 EPS growth of only 3.5%.
• Monitor key indicators such as growth in unique provider engagement, the tangible impact of new AI tools like Doximity GPT on client retention and upsell opportunities, and the evolving competitive landscape with peers like GDRX and VEEV.
• Given the current Zacks Rank #3 (Hold) and Value Score of D, a cautious approach is advisable; current holders might maintain positions while prospective investors should carefully assess if the growth outlook justifies the valuation, especially in light of the stock's 9.6% year-to-date appreciation.